Biogen pulls European application for Aduhelm in another setback for the Alzheimer's drug

Biogen has withdrawn a request to start selling its Alzheimer's disease drug in Europe, marking the latest setback in the company's efforts to ramp up slower-than-expected sales of the closely watched medicine.